Evista is a brand name of raloxifene, approved by the FDA in the following formulation(s):
EVISTA (raloxifene hydrochloride - tablet; oral)
Manufacturer: LILLY
Approval date: December 9, 1997
Strength(s): 60MG [RLD]
Has a generic version of Evista been approved?
No. There is currently no therapeutically equivalent version of Evista available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Evista. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Methods for inhibiting bone loss
Patent 5,393,763
Issued: February 28, 1995
Inventor(s): Black; Larry J. & Cullinan; George J.
Assignee(s): Eli Lilly and Company
The current invention provides methods and pharmaceutical formulations that are useful for inhibiting the loss of bone. These methods and formulations can be used without the associated adverse effects of estrogen therapy, and thus serve as an effective and acceptable treatment for osteoporosis.Patent expiration dates:
- July 28, 2012✓✓
- July 28, 2012
Method for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[B][2-(piperidin-1-yl)ethoxyphenylime thanone hydrochloride
Patent 5,457,117
Issued: October 10, 1995
Inventor(s): Black; Larry J. & Cullinan; George J.
Assignee(s): Eli Lilly and Company
The current invention provides a method useful for inhibiting the loss of bone using 6-hydroxy-2-(4-hydroxyphenyl)-benzo(B)thien-3-yl-4[2-(piperidin-1-ethoxyph enol]methanone hydrochloride.Patent expiration dates:
- July 28, 2012✓✓
- July 28, 2012
Methods of use for inhibiting bone loss and lowering serum cholesterol
Patent 5,478,847
Issued: December 26, 1995
Inventor(s): Draper; Michael W.
Assignee(s): Eli Lilly and Company
A method of inhibiting bone loss or resorption, or lowering serum cholesterol, comprising administering to a human in need thereof a compound having the formula ##STR1## or a pharmaceutically acceptable salt or solvate thereof, in a low dosage amount. Also encompased by the invention is a a pharmaceutical formulation in unit dosage form comprising, per unit dosage, a low dosage amount.Patent expiration dates:
- March 2, 2014✓✓
- March 2, 2014
Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
Patent 5,811,120
Issued: September 22, 1998
Inventor(s): Gibson; Lowell L. & Hartauer; Kerry J. & Stowers; Julian L. & Sweetana; Stephanie A. & Thakkar; Arvind L.
Assignee(s): Eli Lilly and Company
This invention provides solid orally administerable pharmaceutical formulations comprising raloxifene hydrochloride, a surfactant being sorbitan fatty acid ester or a polyoxyethylene sorbitan fatty acid ester, polyvinylpyrrolidone, and a water soluble diluent which is polyol or sugar.Patent expiration dates:
- March 2, 2014
- March 2, 2014
Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
Patent 5,972,383
Issued: October 26, 1999
Inventor(s): Gibson; Lowell L. & Hartauer; Kerry J. & Stowers; Julian L. & Sweetana; Stephanie A. & Thakkar; Arvind L.
Assignee(s): Eli Lilly and Company
This invention provides orally administerable pharmaceutical formulations comprising raloxifene, its ethers or esters, or a pharmaceutically-acceptable salt thereof, in combination with a hydrophilic carrier composition.Patent expiration dates:
- March 2, 2014✓
- March 2, 2014
Benzothiophenes formulations containing same and methods
Patent 6,458,811
Issued: October 1, 2002
Inventor(s): Gordon Nelson; Arbuthnot & Brian Weston; Dalder & Kerry John; Hartauer & Wayne Douglas; Luke & Robert Eugene; Stratford, Jr.
Assignee(s): Eli Lilly and Company
This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.Patent expiration dates:
- March 10, 2017✓✓✓
- March 10, 2017
Benzothiophenes, formulations containing same, and methods
Patent 6,797,719
Issued: September 28, 2004
Inventor(s): Gordon Nelson; Arbuthnot & Brian Weston; Dalder & Kerry John; Hartauer & Wayne Douglas; Luke & Robert Eugene; Stratford, Jr.
Assignee(s): Eli Lilly and Company
This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.Patent expiration dates:
- March 10, 2017✓
- March 10, 2017
Benzothiophenes, formulations containing same, and methods
Patent 6,894,064
Issued: May 17, 2005
Inventor(s): Arbuthnot; Gordon Nelson & Dalder; Brian Weston & Hartauer; Kerry John & Luke; Wayne Douglas & Stratford, Jr.; Robert Eugene
Assignee(s): Eli Lilly and Company
This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.Patent expiration dates:
- March 10, 2017✓✓
- March 10, 2017
Methods for inhibiting bone loss
Patent 6,906,086
Issued: June 14, 2005
Inventor(s): Black; Larry J.
Assignee(s): Eli Lilly and Company
The current invention provides methods and pharmaceutical formulations that are useful for inhibiting the loss of bone. These methods and formulations can be used without the associated adverse effects of estrogen therapy, and thus serve as an effective and acceptable treatment for osteoporosis.Patent expiration dates:
- July 28, 2012✓
- July 28, 2012✓
- July 28, 2012
Benzothiophenes, formulations containing same, and methods
Patent 8,030,330
Issued: October 4, 2011
Inventor(s): Arbuthnot; Gordon Nelson & Dalder; Brian Weston & Hartauer; Kerry John & Luke; Wayne Douglas & Stratford, Jr.; Robert Eugene
Assignee(s): Eli Lilly and Company
This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.Patent expiration dates:
- March 10, 2017✓
- March 10, 2017
Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
Patent RE38968
Issued: February 7, 2006
Inventor(s): Black; Larry J. & Cullinan; George J.
Assignee(s): Eli Lilly and Company
The current invention provides a method useful for inhibiting the loss of bone using 6-hydroxy-2-(4-hydroxyphenyl)-benzo(B)-thien-3-yl-4[2-piperidin-1-ethoxyphenol]methanone hydrochloride.Patent expiration dates:
- July 28, 2012✓
- July 28, 2012✓
- July 28, 2012
Methods for inhibiting bone loss
Patent RE39049
Issued: March 28, 2006
Inventor(s): Black; Larry J. & Cullinan; George J.
Assignee(s): Eli Lilly and Company
The current invention provides methods and pharmaceutical formulations that are useful for inhibiting the loss of bone. These methods and formulations can be used without the associated adverse effects of estrogen therapy, and thus serve as an effective and acceptable treatment for osteoporosis.Patent expiration dates:
- July 28, 2012✓
- July 28, 2012✓
- July 28, 2012
Methods of use for inhibiting bone loss and lowering serum cholesterol
Patent RE39050
Issued: March 28, 2006
Inventor(s): Draper; Michael W. & Black; Larry J.
Assignee(s): Eli Lilly and Company
A method of inhibiting bone loss or resorption, or lowering serum cholesterol, comprising administering to a human in need thereof a compound having the formula or a pharmaceutically acceptable salt or solvate thereof, in a low dosage amount. Also encompassed by the invention is a a pharmaceutical formulation in unit dosage form comprising, per unit dosage, a low dosage amount.Patent expiration dates:
- March 2, 2014✓
- March 2, 2014✓
- March 2, 2014
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- September 13, 2010 - REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER
- September 13, 2014 - ORPHAN DRUG EXCLUSIVITY
See also...
- Evista Consumer Information (Drugs.com)
- Evista Consumer Information (Wolters Kluwer)
- Evista Consumer Information (Cerner Multum)
- Evista Advanced Consumer Information (Micromedex)
- Evista AHFS DI Monographs (ASHP)
- Raloxifene Consumer Information (Wolters Kluwer)
- Raloxifene Consumer Information (Cerner Multum)
- Raloxifene Advanced Consumer Information (Micromedex)
- Raloxifene Hydrochloride AHFS DI Monographs (ASHP)
No comments:
Post a Comment